0001209191-23-056786.txt : 20231128 0001209191-23-056786.hdr.sgml : 20231128 20231128161924 ACCESSION NUMBER: 0001209191-23-056786 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231125 FILED AS OF DATE: 20231128 DATE AS OF CHANGE: 20231128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Macrae Sandy CENTRAL INDEX KEY: 0001675687 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 231446701 MAIL ADDRESS: STREET 1: 721 ST. GEORGES ROAD CITY: PHILADELPHIA STATE: PA ZIP: 19119 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001675687 Macrae Sandy C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 1 1 0 0 President, CEO and Director 0 Common Stock 2023-11-25 4 F 0 10411 0.3821 D 592476 D Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on November 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on November 24, 2023 of $0.3821/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. Includes: (a) 10,589 shares resulting from the November 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 105,000 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Alexander D. Macrae, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-11-28